Skip to main content

Maternal-Fetal Relations

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

March Biosciences
March BiosciencesTX - Houston
1 program
Determinants of Fetal Inflammatory Exposure at TermN/A1 trial
Active Trials
NCT00970151Completed618Est. Aug 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
March BiosciencesDeterminants of Fetal Inflammatory Exposure at Term

Clinical Trials (1)

Total enrollment: 618 patients across 1 trials

NCT00970151March BiosciencesDeterminants of Fetal Inflammatory Exposure at Term

Determinants of Fetal Inflammatory Exposure at Term

Start: Jun 2005Est. completion: Aug 2009618 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.